Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients

Eugenia Negredo, Amy H. Warriner

    Research output: Contribution to journalReview articleResearchpeer-review

    13 Citations (Scopus)


    © 2016 Wolters Kluwer Health, Inc. All rights reserved. Purpose of review Osteoporosis is a growing concern among people living with HIV (PLWH) because of the recognized risk of fractures, which bring with them morbidity and mortality. New evidence is helping clinicians understand how to prevent and manage osteoporosis in this subpopulation. Recent findings The benefit of calcium and Vitamin D is variable in osteoporosis literature in general, but evidence supports the use of these supplements in PLWH to prevent the loss of bone mineral density when initiating antiretroviral therapy and in enhancing the effectiveness of antiosteoporosis treatments. Of the osteoporosis treatments, alendronate and zoledronate are the only two with substantial evidence of safety and effectiveness in PLWH, but the studies have been small and of limited duration. There are no randomized controlled studies of raloxifene, denosumab or teriparatide in PLWH. Of increasing interest is the possible benefit of statins on bone health through decreased inflammation. Summary Osteoporosis is recognized as an issue for PLWH. Although some of the available osteoporosis treatments have proven safe and effective, future studies of the novel treatments, such as statins, along with welldesigned studies of established osteoporosis treatments for use in PLWH are needed to further guide the clinical management of osteoporosis in this population.
    Original languageEnglish
    Pages (from-to)351-357
    JournalCurrent Opinion in HIV and AIDS
    Issue number3
    Publication statusPublished - 1 Jan 2016


    • Bisphosphonates
    • HIV
    • Osteoporosis
    • Statins


    Dive into the research topics of 'Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients'. Together they form a unique fingerprint.

    Cite this